In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
about
Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics.Pharmacological and pharmaeconomic considerations.Pharmacokinetic and pharmacodynamic integration and modeling of acetylkitasamycin in swine for Clostridium perfringens.
P2860
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@en
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@nl
type
label
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@en
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@nl
prefLabel
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@en
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@nl
P2093
P2860
P1476
In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin.
@en
P2093
P2860
P304
P356
10.1179/JOC.2002.14.6.584
P577
2002-12-01T00:00:00Z